Cantor Fitzgerald Maintains Neutral on Aleafia Health, Raises Price Target to C$0.09
Cantor Fitzgerald analyst Pablo Zuanic maintains Aleafia Health (TSX:AH) with a Neutral and raises the price target from C$0.08 to C$0.09.
Aleafia Health Hits Record $43.1M Net Revenue In 2022 15-Month Fiscal Year, Closes Debenture Amendment Transaction
Aleafia Health Inc. (OTCQX: ALEAF) (TSX:AH) revenue for the 12 months period ending March 31, 2022 was $46.3 million compared to $30.08 million in the12 month period ending March 31, 2021. The fiscal year was changed to end on March 31.
Aleafia Health Reaffirms Revenue Guidance, Implements $6.7 Million In Annualized Cost Savings
Aleafia Health Inc. (TSX:AH) (OTCQX: ALEAF) reaffirmed its guidance with an announcement that it expects to achieve between $53 million and $63 million in net revenue in the current fiscal year.
‘Canadian Cannabis Stocks Fall 1.4% in March’ -Article From Alan Brochstein’s New Cannabis Ventures
https://www.newcannabisventures.com/canadian-cannabis-stocks-fall-1-4-in-march/
Cantor Fitzgerald Maintains Neutral on Aleafia Health, Lowers Price Target to C$0.13
Cantor Fitzgerald analyst Pablo Zuanic maintains Aleafia Health (TSX:AH) with a Neutral and lowers the price target from C$0.22 to C$0.13.
The Week In Cannabis: Schumer’s Bill, The Super Bowl, Leafly, Canopy Growth, Tilray, Hexo, Sundial And More
Below is a recap of the main news related to the cannabis industry and markets for the week of February 7, 2022.
Contents
Aleafia Health Closes New $19M Credit Facility, Improves Financial Flexibility
Aleafia Health Inc. (TSX: AH) (OTCQX: ALEAF) announced Wednesday that it is closing its credit facility of up to $19 million.
The financing provides the Toronto-based company with liquidity to fund operations and organic growth initiatives.
The Week In Cannabis: Earnings Season, A GOP Legalization Bill, Seth Rogen & Sarah Silverman’s Campaign
Below is a recap of the main news related to the cannabis industry and markets for the week of November 8, 2021.
Contents
Cantor Fitzgerald Maintains Neutral on Aleafia Health, Lowers Price Target to C$0.22
Cantor Fitzgerald analyst Pablo Zuanic maintains Aleafia Health (TSX:AH) with a Neutral and lowers the price target from C$0.42 to C$0.22.
Aleafia Health’s Q3 Cannabis Revenue Grows 123% YoY, Reports Higher Net Loss, Negative Adjusted EBITDA
Vertically-integrated cannabis company Aleafia Health Inc. (TSX: AH) (OTCQX: ALEAF) reported its third-quarter earnings Thursday with net cannabis revenue of $9.49 million, representing an improvement of 123% from $4.25 million in the same period of the prior year.